

**Harvard Medical School
Curriculum Vitae**

Date Prepared: May 20, 2016
Name: Matthew H. Kulke
Office Address: Dana-Farber Cancer Institute
450 Brookline Ave, D 1220A
Boston, MA 02215 United States
Home Address: 35 Priscilla Circle
Wellesley, MA 02481 United States
Work Phone: (617) 632-5136
Work Email: matthew_kulke@dfci.harvard.edu
Work FAX: (617) 632-5370
Place of Birth: Palo Alto, CA

Education

1987	B.A. <i>Magna cum laude</i>	Molecular Biology	Princeton University, Princeton, NJ
1992	MD Alpha Omega Alpha	Medicine	University of California, San Francisco School of Medicine San Francisco, CA
2007	M.M.Sc.	Medicine	Harvard Medical School Boston, MA

Postdoctoral Training

07/01/1992- 06/30/1993	Intern	Medicine	Brigham and Women's Hospital, Boston, MA
07/01/1993- 06/30/1994	Junior Assistant Resident	Internal Medicine	Brigham and Women's Hospital,
07/01/1994- 06/30/1995	Senior Assistant Resident	Internal Medicine	Brigham and Women's Hospital,
07/01/1995- 06/30/1997	Clinical Fellow	Oncology	Dana-Farber Cancer Institute (DFCI), Boston, MA

Faculty Academic Appointments

07/97-06/01	Instructor	Medicine	Harvard Medical School
07/01-06/08	Assistant Professor	Medicine	Harvard Medical School

07/08- Associate Professor Medicine Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

07/97- Associate Physician Medicine Brigham and Women's Hospital
07/97- Attending Physician Medical Oncology Dana-Farber Cancer Institute
07/12- Senior Physician Medical Oncology Dana-Farber Cancer Institute

Major Administrative Leadership Positions

2010- Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston, MA

Committee Service

Local

1998-2008 Chairperson, Cardiopulmonary Resuscitation (CPR) Committee Dana-Farber Cancer Institute
1998-2005 Member, Fellowship Selection Committee Dana-Farber Cancer Institute
2007-2008 Member, Scientific Progress Review Committee Dana-Farber Cancer Institute
2010- Chair, Clinical Information and Biospecimen User Committee, Gastrointestinal Cancer Center Dana-Farber Cancer Institute

National

2005-2010 Member, National Comprehensive Cancer Network Neuroendocrine Tumor Guidelines Panel Fort Washington, PA
2010- Chair, National Comprehensive Cancer Network Neuroendocrine Tumor Guidelines Panel Fort Washington, PA

International

2008-2010 Member, Data Safety Monitoring Committee, First-Line Advanced Gastric Cancer Study (FLAGS) Taiho Pharmaceuticals, Tokyo, Japan
2010-2013 Member, Data Safety Monitoring Committee, RAD001 in Advanced Novartis Pharmaceuticals, Basel, Switzerland

2011-	Neuroendocrine Tumors (RADIANT) 2 and RADIANT 3 Studies Chair, Steering Committee, Efficacy of Everolimus Alone or in Combination with Pasireotide Long-acting Release (LAR) in Advanced Pancreatic Neuroendocrine Tumor (PNET) (COOPERATE)-2 Study	Novartis Pharmaceuticals, Basel, Switzerland
2012-	Member, Steering Committee, RADIANT-4 Study	Novartis Pharmaceuticals, Basel, Switzerland
2013-	Chair, Steering Committee, Telotristate Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome (TELESTAR) Study	Lexicon Pharmaceuticals, The Woodlands, TX

Professional Societies

1992-	Massachusetts Medical Society	Member
1997-	American Society of Clinical Oncology	Member
2001-	Cancer and Leukemia Group B	
	2001-2010	Member
	2010-	Member, Gastrointestinal Cancer Core Committee
2006-	North American Neuroendocrine Tumor Society	
	2006-2012	Co-Chair, Scientific Research Committee
	2012-2014	Vice-Chair
	2014-	Chair
2008-	European Neuroendocrine Tumor Society	Member, External Advisory Board
2009-	National Cancer Institute Neuroendocrine Tumor Task Force	
	2009-2010	Member
	2010-2014	Chair
2009-	American Association for Cancer Research	Member
		Member

Editorial Activities

***Ad hoc* Reviewer**

Journal of Clinical Oncology
Cancer
Clinical Cancer Research
Endocrine Related Cancer
New England Journal of Medicine

Other Editorial Roles

2000-	Editor	UpToDate in Medicine (Neuroendocrine Tumor Section)
2001-2003	Editorial Board	Journal of Clinical Oncology

Honors and Prizes

1987	Regents Scholarship	University of California, San Francisco School of Medicine, San Francisco, CA
1989-1992	Medical Student Research Training Fellowship	Howard Hughes Medical Institute, University of California, San Francisco School of Medicine, San Francisco, CA
1991	Alpha Omega Alpha Medical Honor Society	University of California, San Francisco School of Medicine
1998-1999	Young Investigator Award	American Society of Clinical Oncology
1999-2001	Discovery Fellowship	Dana-Farber Cancer Institute
2003	George Canellos Award for Contributions to Clinical Research	Dana-Farber Cancer Institute
2008	Kenneth E Schwarz Center Compassionate Care Giver Award	Dana-Farber Cancer Institute
2009	Ruth Brufsky Award for Excellence in Clinical Research on Pancreatic Cancer Research	University of Pittsburgh School of Medicine
2010	Lee Nadler Extra Mile Award	Dana-Farber Cancer Institute
2011	Kenneth E Schwarz Center Compassionate Care Giver Award	Dana-Farber Cancer Institute

Report of Funded and Unfunded Projects

Past

1997-2000	Principal Investigator, Rhone-Poulenc Rorer., DF/HCC Protocol # 97-121, Phase II Study of Docetaxel in Patients with Locally Advanced or Unresectable Carcinoid Tumors The objective of this study was to assess the efficacy of docetaxel in patients with locally advanced or unresectable carcinoid tumors.
1999-2001	Principal Investigator, Eli-Lilly., DF/HCC Protocol # 99-044, Phase II Study of Gemcitabine in Patients with Advanced Neuroendocrine Tumors The objective of this study was to assess the efficacy of gemcitabine in patients with advanced neuroendocrine tumors.
2000-2002	Principal Investigator, Glaxowellcome., DF/HCC Protocol # 00-012, Phase II Study of Vinorelbine in Patients with Unresectable or Metastatic Esophageal or Gastric Adenocarcinoma The objective of this study was to assess the efficacy of vinorelbine in patients with unresectable or metastatic esophageal or gastric adenocarcinoma.
2001-2003	Principal Investigator, Pharmacia & Upjohn., DF/HCC Protocol # 01-100, Phase II Study of Irinotecan and Cisplatin in Patients with Advanced Neuroendocrine Tumors The objective of this study was to assess the efficacy of irinotecan and cisplatin

- in patients with advanced neuroendocrine tumors
- 2001-2003 Principal Investigator, Entremed, DF/HCC Protocol # 01-114, Phase II Study of the Safety and Efficacy of Recombinant Human Endostatin in Patients with Advanced Neuroendocrine Tumors
The objective of this study was to assess the efficacy of recombinant human endostatin in patients with advanced neuroendocrine tumors.
- 2001-2004 Principal Investigator, CALGB 89904, A Randomized Phase II trial of Gemcitabine/Cisplatin, Gemcitabine/Irinotecan, Gemcitabine/Docetaxel, or Fixed Dose Rate Infusion Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Cancer
The objective of this study was to compare the efficacy of gemcitabine/cisplatin, gemcitabine/irinotecan, gemcitabine/docetaxel, or fixed dose rate infusion gemcitabine in patients with metastatic pancreatic cancer.
- 2002-2004 Principal Investigator, Celgene., DF/HCC Protocol # 02-011, A Phase II Study of Temozolomide and Thalidomide in Patients with Metastatic Neuroendocrine Tumors
The objective of this study was to assess the efficacy of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
- 2003-2004 Principal Investigator, Sugen Inc., DF/HCC Protocol # 02-317, A Phase II Study of the Efficacy and Safety of SU011248 in Patients with Advanced Unresectable Neuroendocrine Tumor (Multicenter Study)
The objective of this multi-institutional study was to assess the efficacy of SU011248 (sunitinib) in patients with advanced unresectable neuroendocrine tumors.
- 2003-2004 Principal Investigator, Roche Inc., DF/HCC Protocol # 03-070, A Phase II Study of OSI-774 (Tarceva) in Combination with Capecitabine in Patients with Metastatic Pancreatic Cancer
The objective of this study was to assess the efficacy of OSI-774 (Tarceva) in combination with capecitabine in patients with metastatic pancreatic cancer.
- 2003-2004 Principal Investigator, Taiho Inc, DF/HCC Protocol 03-209, Phase I Study of S-1 in Patients with Previously Treated Upper GI Malignancies
The objective of this study was to assess the efficacy of the oral fluoropyrimidine S-1 in patients with previously treated upper GI malignancies.
- 2003-2008 Principal Investigator, National Institute of Health (NIH)/National Cancer Institute (NCI), K23 CA 093401, Molecular Prognostic Factors in Esophageal Cancer
The objective of this career-development award was to assess the prognostic significance of germline polymorphisms and tissue-based markers in esophageal cancer.
- 2004-2005 Principal Investigator, Genentech., DF/HCC Protocol # 04-272, Phase II Study of Temozolomide and Bevacizumab in Patients with Advanced Neuroendocrine Tumors
The objective of this study was to assess the efficacy of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors.
- 2004-2006 Principal Investigator, Astra-Zeneca, DF/HCC Protocol # 04-173, A Phase II Study of Iressa in Combination with Docetaxel in Patients with Metastatic Pancreatic Cancer
The objective of this study was to assess the efficacy of iressa in combination

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.